| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Multiple myeloma cells acquire the resistance to anti-cancer drugs via interaction with bone marrow stroma (cell adhesion-mediated drug resistance). In this study, we investigated the role of circulating microvescles (cMV) produced by myeloma cells in cell adhesion-mediated drug resistance. We isolated cMV from the co-culcture supernatant of myeloma cells and human bone marrow-derived stromal cells.We then extracted total RNA form cMV and subjected them to microRNA arrays, and found that myeloma-derived cMV was very rich in miR-155 and mir-135b. Functional studies revealed that the expression level of miR-155 was positively correlated with the sensitivity of myeloma cells to proteasome inhibitors. We are currently investigating the precise mechanisms by which miR-155 determines the sensitivity of myeloma cells to proteasome inhibitors.
|
